NMNhu Nguyen Tran Minh

Nhu Nguyen Tran Minh

*This is an algorithmically generated author record based on publicly available information.

Nhu Nguyen Tran Minh has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Heikki Arvilommi

    National Public Health Institute, Department in Turku, Kiinamyllynkatu 13, Fin-20520, Turku, Finland

    3 shared publications
  • Jussi Mertsola

    National Public Health Institute, Department in Turku, Kiinamyllynkatu 13, Fin-20520, Turku, Finland

    3 shared publications
  • Qiushui He

    National Public Health Institute, Department in Turku, Kiinamyllynkatu 13, Fin-20520, Turku, Finland

    3 shared publications
  • Kati Edelman

    National Public Health Institute, Department in Turku, Kiinamyllynkatu 13, Fin-20520, Turku, Finland

    2 shared publications
  • Matti K. Viljanen

    From the National Public Health Institute, Department in Turku

    2 shared publications
  • Achim Kaufhold

    SmithKline Beecham Biologicals, Rixensart, Belgium

    1 shared publication

Latest Publications

  • Immune responses to pertussis antigens eight years after booster immunization with acellular vaccines in adults

    by Nhu Nguyen Tran Minh, Qiushui He, Kati Edelman, Anne Putto-Laurila, Heikki Arvilommi, Matti K Viljanen, Jussi Mertsola


  • Acellular Vaccines Containing Reduced Quantities of Pertussis Antigens as a Booster in Adolescents

    by Nhu Nguyen Tran Minh, Qiushui He, Anya Ramalho, Achim Kaufhold, Matti K. Viljanen, Heikki Arvilommi, Jussi Mertsola

    Objective.: To evaluate the immunogenicity and reactogenicity of an acellular pertussis vaccine (pa) either formulated with diphtheria and tetanus toxoids (dTpa) or administered consecutively with a licensed tetanus and diphtheria vaccine (Td) as a 5th dose in adolescents.Methods.: A total of 510 healthy children 10 to 13 years of age were assigned randomly, using a single-blind design, to receive either the dTpa vaccine or the Td vaccine with the pa vaccine 1 month later. The quantities of 3 pertussis antigens (pertussis toxin, filamentous hemagglutinin, and pertactin) in the dTpa and the pa vaccines were one third of those of the Infanrix vaccine (SmithKline Beecham Biologicals, Rixensart, Beligium) licensed for use in infants. For enzyme-linked immunosorbent assay measurement of serum immunoglobulin G antibodies and proliferation assay of peripheral blood mononuclear cells, blood samples were obtained before and 1 month after immunization. Local and systemic reactions were recorded on diary cards for 15 days after immunization.Results.: After immunization with dTpa or pa, significant and comparable rises in geometric mean values of antibodies (12- to 46-fold) and proliferations (8- to 18-fold) to each of the pertussis antigens were noted. After immunization with dTpa or Td, significant rises in geometric mean values of antidiphtheria and antitetanus antibodies (35- to 76-fold) were noted, and all subjects had values of these antibodies ≥.1 international units/mL. The dTpa and pa vaccines were at least as well tolerated as the licensed Td vaccine.Conclusions.: Booster immunization of adolescents with an acellular vaccine containing reduced quantities of pertussis antigens in addition to diphtheria and tetanus toxoids induces good responses in both arms of the immune system without an increase in adverse reactions.


  • Cell-mediated immune responses to antigens of Bordetella pertussis and protection against pertussis in school children

    by Nhu Nguyen Tran Minh, Qiushui He, Kati Edelman, Rose-Marie Msc Ölander, Matti K. Viljanen, Heikki Arvilommi, Jussi Mertsola

    Background. Increasing evidence suggests that cell-mediated immunity (CMI) is involved in immune response against Bordetella pertussis. However, there are practically no studies evaluating the significance of pertussis-specific CMI in relation to protection against clinical pertussis. Methods. An outbreak of pertussis was studied prospectively in 13-year-old pupils in a rural school. B. pertussis infection was diagnosed by culture, microagglutination and enzyme immunoassay serology with the use of pertussis toxin, filamentous hemagglutinin and pertactin as antigens. Pertussis-specific CMI responses were assessed by in vitro proliferation assay of peripheral blood mononuclear cells. Results. At the initial sampling 7 of 22 children had symptoms suggestive of pertussis and 15 were asymptomatic. Of the latter 3 remained healthy, 8 were later confirmed to have had asymptomatic infection, 3 developed laboratory-confirmed pertussis and 1 developed cough without laboratory evidence of pertussis. Initial in vitro proliferations of peripheral blood mononuclear cells induced by pertussis toxin, filamentous hemagglutinin and/or pertactin were positive in all 3 healthy children, in 6 of 8 children who had asymptomatic infection, but in none of the 3 children who later developed pertussis. Although some children who remained healthy had high values of antibodies, no clear association was found between initial serum antibody values and clinical outcome. Conclusions. These preliminary data suggest that CMI may have an important role in protection against clinical pertussis but do not exclude a role for antibodies. Furthermore the results stress a multifactorial nature of the immune protection against B. pertussis.


  • Antibody and cell-mediated immune responses to booster immunization with a new acellular pertussis vaccine in school children

    by N.N. Tran Minh, K. Edelman, Q. He, M.K. Viljanen, H. Arvilommi, J. Mertsola